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Abstract: Tumor necrosis factor-related apoptosis-inducing ligand
is a type II membrane-bound protein whose C-terminal extracellular
domain shows clear homology to other tumor necrosis factor family
members. It is constitutively expressed on macrophages, T cells,
natural killer cells, and dendritic cells and selectively kills trans-
formed cells leaving most of the normal cells alone. This selectivity
has led to great interest in it use as a therapeutic agent for the
treatment of malignancy. In this review, this critical pathway is
described, highlighting its mechanistic manipulation for therapeutic
benefit and the recent phase I and II trials in lung cancer that have
been performed or are currently ongoing are also discussed.
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In 1995, Wiley et al. characterized tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) as a new mem-
ber of the tumor necrosis factor (TNF) family that induces
apoptosis. The protein, designated TRAIL, consists of 281
and 291 amino acids in the human and murine forms, respec-
tively, which share 65% amino acid identity.1 The TRAIL
gene is located on chromosome 3 at position 3q26 and is
isolated from other known TNF ligand family members.
TRAIL also exists in a soluble form (sTRAIL) generated
through enzymatic shedding or released in microvesicles.2,3
TRAIL transcripts are detected in a variety of human tissues,
most predominantly in spleen, lung, and prostate. Originally,
one TRAIL receptor was discovered, which was widely
found on transformed and normal cells. Further studies
quickly progressed and three more receptors (one death
receptor and two decoy receptors) on the cell surface and one
soluble receptor named osteoprotegerin were discovered. The
cell surface death receptors (DRs) are designated Trail-DR4
(TRAIL-R1) and DR5 (TRAIL-R2). The decoy receptors are
identified as Dc-1 (TRAIL-R3) and Dc-R2 (TRAIL-R4).
Osteoprotegerin is a soluble decoy receptor for TRAIL,
which exists as a dimer in its active form.4
The death receptors have cytoplasmic death domains,
which can activate both caspases and nuclear factor kappa-
light-chain-enhancer of activated B cells. The decoy recep-
tors have truncated death domains, which do not conduct a
stimulating signal and thus divert TRAIL away from the
competing functional death receptor. TRAIL is constitutively
expressed on macrophages, natural killer cells, T cells, and
dendritic cells.4
Animal studies have greatly enhanced our under-
standing of TRAIL. In mice, a single membrane TRAIL
death receptor has been identified, which shows the highest
sequence homology with human DR5. Like humans, mice
have two decoy receptors that do not have transmembrane
domains.5
In 2002, Cretney et al. and Sedger et al. published the
first results from TRAIL-deficient mice. Both studies re-
ported that the mice were viable and fertile, showed no gross
phenotype, and did not display any developmental defects
indicating that TRAIL has no crucial role in embryonic
development.5,6 Research on TRAIL-R-deficient mice re-
vealed similar findings.7,8 Later work suggested that these
mice had a tendency to spontaneous tumor formation and the
development of autoimmune disease.9
Major roles for the TRAIL/TRAIL-R system were
subsequently identified in the immune system. TRAIL has
been shown to influence infections and inflammatory diseases
while also playing a role in the immune surveillance of
tumors and metastasis.9 Both full-length cell surface ex-
pressed TRAIL and picomolar concentrations of soluble
TRAIL rapidly induce apoptosis in a wide variety of trans-
formed cells, but importantly, unlike other members of the
TNF superfamily (TNF- and FAS ligand) that tend to leave
normal cells alone. TRAIL’s ability to selectively kill trans-
formed cells made it an attractive therapeutic target for
disease such as cancer.
TRAIL-induced target cell apoptosis begins with the bind-
ing of TRAIL to a death receptor (TRAIL-DR4/5) (Figure 1).
The death receptor forms a trimer with two other bound death
receptors (these trimers are associated through preligand assem-
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bly domain and preligand-binding assembly domains) leading to
the recruitment of FAS-associated death domain to the receptor
complex (through DD interactions).O-glycosylation of DR4 and
DR5 and palmitoylation of DR4 facilitate ligand-induced recep-
tor clustering (extrinsic pathway). This process results in the
formation of the death-inducing signalling complex (DISC),
which is made up of oligomerized receptors, the adaptor mole-
cule FAS-associated death domain, the initiator proteases
caspase-8 and/or caspase-10, and, depending on the context, the
cellular FADD-like interleukin-1 beta-converting enzyme-like
inhibitory protein (c-FLIP).
The DISC moves into a lipid-rich membrane compart-
ment where caspase-8 comes into contact with a CUL3/RbxI-
based E3 ligase complex, which results in the polyubiquitylation
of caspase-8 on its C-terminal region. Polyubiquitylated
caspase-8 associates with the ubiquitin-binding protein p62/
sequestosome-1, thus promoting the translocation of caspase-8
from the DISC into ubiquitin-rich intracellular foci.10 This pro-
cess increases the focal concentration of caspase-8, facilitating
its full activation.
c-FLIP, an apoptosis inhibitor, can also be recruited to
the DISC, inhibiting caspase-8 recruitment and activation,
exerting an antiapoptotic effect. Caspases-8 and -10 then
cleave and activate the effector caspases-3, -6, and -7, which
execute the apoptotic death program. Although this process
operates effectively in type I cells, amplification of apoptosis
in type II cells requires activation of the mitochondrial
intrinsic pathway.10
The intrinsic pathway involves TRAIL receptor bind-
ing-induced apoptosis through the cleavage of B-cell lym-
phoma (BCL)-2 interacting domain by caspase-8, which then
translocates to the mitochondrial membrane causing a con-
formational change in associated X protein (Bax), which
along with the Bcl-2 homologous antagonist/killer (Bak)
forms a pore in the membrane allowing the release of cyto-
chrome c. This step can be inhibited by BCL-2. Cytochrome
c and apoptotic protease-activating factor 1 form the apopto-
some, which in turn recruits procaspase-9, activating it and
allowing it to cleave caspase-3 into an active form. Caspase-3
and -9 may be inhibited by X-linked inhibitor of apoptosis
protein (XIAP).
TRAIL binding can also activate prosurvival signaling
pathway with the recruitment of TNF receptor-associated
factor 2, which can activate multiple kinase pathways and
FIGURE 1. TRAIL induces apoptosis of transformed or malignant cells through both the intrinsic (mitochondrial) and extrinsic
(death receptor/caspase) pathway. TRAIL, tumor necrosis factor-related apoptosis-inducing ligand.
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nuclear factor kappa-light-chain-enhancer of activated B cells
leading to cell proliferation and to the transcription of anti-
apoptotic genes promoting the expression of antiapoptotic
proteins such as c-FLIP and XIAP.11–13
Both the intrinsic and extrinsic pathways are closely
regulated at different levels, balancing the pro- and antiapo-
ptotic signals. Apoptosis inhibitors such as c-FLIP, BCL-2
family, and XIAP can inhibit TRAIL’s function. These in-
hibitors can be up-regulated in many tumor types rendering
the tumors resistant to TRAIL-induced death.14,15 Moreover,
mutations in the TRAIL death receptors have also been found
in tumors including non-small cell lung cancer (NSCLC)
rendering them resistant to TRAIL as a therapeutic agent.
Targeting the TRAIL Pathway
The obvious advantage of targeting this pathway is that
TRAIL selectively kills tumor cells, leaving normal cells
alone.16 The exact reason for this is still not completely under-
stood but is probably because of a number of factors including
increased expression of decoy receptors on normal cells and
increased expression of DR4 and DR5 on tumor cells.17
Importantly, TRAIL-induced tumor killing is indepen-
dent of protein 53 (p53) status and therefore TRAIL can
bypass an inactivated P53 pathway, often a reason for drug
therapy resistance.14
Therapeutic agents directed at the TRAIL pathway
have been developed and include recombinant human soluble
TRAIL (rhTRAIL), which has a half-life of 20 to 30 minutes,
and agonistic monoclonal antibodies directed at DR4 and/or
DR5, which have a half-life of 18 to 21 days.14,18
NSCLC seems to be a particularly suitable target for a
TRAIL-based therapy. These tumors express large amounts
of TRAIL DR4 and 5 in the majority of specimens tested.19
An inactive P53 pathway also occurs in 50% of these tumors
conferring chemo/radiotherapy resistance. TRAIL pathway
stimulation allows this p53 pathway to be bypassed.14 Al-
though the DNA damage-induced caspase-9 activation path-
way is disrupted in many patients with NSCLC, the caspase-8
mitochondrial pathway is fully operational allowing TRAIL
to effectively kill the tumor cells in these cases.20,21
Nevertheless, preclinical work on NSCLC revealed that
the tumors were not always susceptible to TRAIL-mediated
killing as first thought. This resistance to TRAIL-mediated
death in NSCLC can occur at various levels in the pathway
with up-regulation of decoy receptors, c-FLIP, and BCL-2
proteins well described.15
Further work has revealed that this resistance is over-
come when combination therapy with other established or
newer agents is introduced.15
For example, standard chemo- or radiotherapy can
thwart this resistance by both p53-dependent and independent
mechanisms resulting in up-regulation of TRAIL receptor
expression and increased intrinsic pathway efficiency.15
Alternatively, Bortezomib, a proteasome inhibitor,
blocks the activity of antiapoptotic proteins including BCL-
XL, XIAP, and c-FLIP at the transcriptional level by inhib-
iting NF-jB activity.14,15,22,23
Unfortunately, unlike NSCLC, small cell lung cancer
(SCLC) is inherently resistant to TRAIL-mediating killing as
these tumor cells lack components of the DISC complex
including caspase-8, a phenomenon attributed to methylation
of the caspase-8 gene.24 Moreover, Belyanskaya et al.25
demonstrated that TRAIL augmented SCLC cell proliferation
and survival through DR5-mediated extracellular signal reg-
ulated kinase 1/2 activation.
Approaches to demethylate caspase-8 using interferon-
have increased SCLC tumor cells to TRAIL-mediated killing.26
Histone deacetylase inhibitors such as valproic acid and
trichostatin A have been shown to sensitize tumors to
TRAIL-mediated death. In general, these agents elevate death
receptors and suppress apoptotic inhibitors.27 In the case of
NSCLC, these agents increase TRAIL-induced caspase ac-
tivity, although their use in SCLC has not been reported.28,29
Other studies investigating TRAIL resistance have
shown that the use of TRAIL in combination with etoposide
or doxorubicin on SCLC cell lines leads to up-regulation of
TRAIL-R2 and down-regulation of c-FLIP.30
Recent Clinical Trials
Phase I and II clinical trials using recombinant TRAIL
or agonistic monoclonal antibodies to DR4 or DR5 are
running currently.14 Soria et al.31 demonstrated that rhTRAIL
in combination with paclitaxel, carboplatin, and bevacizumab
had a therapeutic benefit in patients with advanced NSCLC.
The primary objective of this study was to determine the
maximum tolerated dose of rhTRAIL; the secondary objec-
tive was to determine pharmacokinetics of this agent. The
sample size was 24 patients. Eligibility criteria included
patients 18 years, stage IIIb/IV nonsquamous NSCLC,
Eastern Cooperative Oncology Group performance status 0 to
1, normal organ function, no brain metastases, and no prior
therapy for NSCLC.31 rhTRAIL was administered intrave-
nously (IV) at 4 or 8 mg/kg/d on days 1 to 5, or at 15 or 20
mg/kg/d on days 1 and 2 of each 21-day cycle. This phase Ib
study in patients with advanced NSCLC showed no dose-
limiting toxicities and an overall response rate of 56%.31,32
A phase II multicenter, open label, randomized study of
AMG 951 (rhTRAIL) in subjects with previously untreated
stage IIIb/IV NSCLC treated with chemotherapy with or
without bevacizumab is currently underway.14,32
Numerous anti-DR5 studies have been performed.
Three of these analyzed the use of this monoclonal antibody
in the treatment of solid tumors.33–35 These studies revealed
that lexatumumab (anti-DR5) therapy while having dose-
related liver toxicity is generally safe when administered at a
dose of 10 mg/kg every 2 weeks.14,33–35 Phase II trials with
this agent in NSCLC as part of combination therapy with
agents such as paclitaxel and carboplatin are ongoing.13
These include a multicenter, randomized, double-blind, pla-
cebo-controlled trial looking at anti-DR5 therapy in combi-
nation with these two agents for first-line treatment of ad-
vanced NSCLC. The study is due for completion in 2013.32
Another is a randomized, double-blind, phase II, placebo-
controlled trial adding on to a background of effective treat-
ment designed to evaluate the efficacy, safety, and pharma-
cokinetics of PRO95780 (anti-DR5) combined with paclitaxel
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carboplatin  bevacizumab therapy in patients with previously
untreated stage IIIB, stage IV, or recurrent NSCLC. Approxi-
mately 120 patients have been randomized to one of two treat-
ment arms, and results are expected later this year.32
Studies have also been published on the use of mono-
clonal agonististic anti-DR4 antibodies.36–39 The majority of
these studies have been phase I clinical trials analyzing the
effect of anti-DR4 alone or in combination with chemother-
apeutic agents in the treatment of malignancy. Mom et al.
enrolled patients with advanced solid tumors to receive gemcit-
abine 1250 mg/m2 IV on days 1 and 8 and cisplatin 80 mg/m2
IV on day 1 of each 21-day cycle. Escalating mapatumumab
(anti-DR4) doses were administered IV every 21 days. Forty-
nine patients received therapy. Adverse events included diar-
rhea, peripheral neuropathy, and reduced appetite.38
A phase II multicenter study was designed to evaluate
the efficacy, safety, and tolerability of mapatumumab in
patients with NSCLC previously treated with at least one
platinum-based regimen. Each patient received mapatu-
mumab (anti-DR4) at a dose of 10 mg/kg administered IV
every 21 days in the absence of disease progression. A total
of 32 patients with relapsed or refractory stage IIIB or IV or
recurrent NSCLC were enrolled. Patients had received a
median of three previous therapeutic regimens (range 1–7).
This study published in 2008 demonstrated no response to
therapy.37 A phase II, randomized, multicenter, open-label
study to evaluate the efficacy and safety of mapatumumab in
combination with carboplatin and paclitaxel as first-line treat-
ment in advanced NSCLC has recently been completed but
results are not yet available.14,32
Data from the ongoing studies (details of which can be
found at www.clinicaltrials.gov) are eagerly awaited as they
may have an important impact on future therapeutic strategies
in the treatment of malignant lung disease.
The manipulation of the TRAIL pathway offers great
therapeutic potential in the treatment of life-threatening ill-
nesses such as lung cancer. Research continues in not only
the field of malignancy but also in areas of infection, inflam-
mation, and immunity. Understanding the subtleties of the
TRAIL system will help us manipulate potential sites in a
pathway that fortunately specifically targets transformed cells
leaving most normal cells alone. Understanding the balance
between the different TRAIL receptors and intrinsic pathway
proteins can only offer further opportunities to render tumors
susceptible to this clean agent.
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